Genevant scores with Take­da again as LNPs con­tin­ue to at­tract in­ter­est for RNA ther­a­py

Bare­ly five months af­ter sign­ing on to a $600 mil­lion deal with Take­da, Genevant has re­turned to ink an­oth­er big biobuck tie-up with its new col­lab­o­ra­tors.

The Cana­di­an and Swiss biotech, spawned out of Vivek Ra­maswamy’s sprawl­ing vant port­fo­lio, has teamed up with Take­da for a li­cens­ing deal to­tal­ing $303 mil­lion, the com­pa­nies an­nounced Mon­day morn­ing. Their fo­cus will re­main on the liv­er, with the new funds fu­el­ing work on non­vi­ral gene ther­a­pies for 2 undis­closed rare liv­er dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER